$0.29 EPS Expected for GoPro (GPRO) This Quarter

Three analysts have provided estimates for GoPro's earnings, with estimates ranging from ($0.33) to ($0.22).

Ricoh has higher revenue and earnings than GoPro. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.04. It has a return on equity (ROE) of -50.70%. The company had revenue of $202.35 million for the quarter, compared to analysts' expectations of $182.26 million. GoPro posted earnings per share of ($0.09) during the same quarter last year, which indicates a negative year over year growth rate of 222.2%. Zacks Investment Research's earnings per share averages are an average based on a survey of sell-side research firms that cover GoPro. (GPRO). A frequently used tool among technical stock analysts is the moving average. BidaskClub downgraded GoPro from a sell rating to a strong sell rating in a research report on Friday, March 23rd. Citigroup reissued a "hold" rating and set a $6.50 price target (up previously from $5.50) on shares of GoPro in a research report on Friday, March 9th. JPMorgan Chase lowered shares of GoPro from an "overweight" rating to a "neutral" rating and decreased their price objective for the stock from $9.00 to $8.00 in a report on Friday, February 2nd. Four investment analysts have rated the stock with a sell recommendation and twelve have given a hold recommendation to the company.

GoPro has a consensus price target of $7.55, indicating a potential upside of 56.96%.

Shares of GPRO opened at $5.56 on Monday. The valid range indicator is the greatest of the following: current high less the current low, the absolute value of the current topless the previous close and the total cost of the current small less the past end. Aveo Pharmaceuticals (NASDAQ:AVEO)'s price to sales ratio for trailing twelve month stands at 36.39, whereas its price to book ratio for the most recent quarters is at 0.

The PEG ratio is used to determine a stock's value while taking the company's earnings growth into account, and is considered to provide a more complete picture than the P/E. Aveo Pharmaceuticals (NASDAQ:AVEO) has a current PEG of 0.

A number of large investors have recently modified their holdings of GPRO. Finally, Creative Planning raised its stake in GoPro by 11.7% in the fourth quarter. North Star Investment Management Corp. now owns 16,575 shares of the company's stock valued at $125,000 after purchasing an additional 11,500 shares during the last quarter. Schwab Charles Investment Management Inc. now owns 621,960 shares of the company's stock worth $6,848,000 after buying an additional 65,097 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of GoPro by 2.7% in the 4th quarter. MUFG Securities EMEA plc grew its stake in shares of GoPro by 958.1% in the fourth quarter. Cubist Systematic Strategies LLC now owns 29,158 shares of the company's stock worth $321,000 after buying an additional 23,508 shares in the last quarter. Finally, Fred Alger Management Inc. lifted its stake in shares of GoPro by 1.3% in the 4th quarter.

Analysts expect GoPro (NASDAQ:GPRO) to report earnings of ($0.29) per share for the current fiscal quarter, according to Zacks.

In other GoPro news, CFO Brian Mcgee sold 11,124 shares of the business's stock in a transaction on Friday, February 16th. ATR remains at 0.3 while Beta component of the stock stands at "Beta". Following the completion of the sale, the chief financial officer now owns 71,958 shares in the company, valued at approximately $406,562.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

In related news, SVP Sharon S. Zezima sold 14,966 shares of the business's stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $5.60, for a total value of $83,809.60. The disclosure for this sale can be found here.